Brivanib is a potent tyrosine kinase inhibitor primarily investigated for the treatment of hepatocellular carcinoma, metastatic colorectal cancer, and other solid tumors. This category offers high-quality… Read more
Brivanib is a potent tyrosine kinase inhibitor primarily investigated for the treatment of hepatocellular carcinoma, metastatic colorectal cancer, and other solid tumors. This category offers high-quality reference standards essential for pharmaceutical laboratories conducting rigorous analytical testing and quality control. Included in this collection are the active pharmaceutical ingredient, the brivanib alaninate prodrug form, and a range of related impurities and metabolites. Researchers utilize these materials for impurity profiling, allowing for the precise identification and quantification of degradation products or synthesis-related impurities. Additionally, this catalogue provides stable isotope labelled compounds, such as deuterium-labelled variants, which serve as internal standards for mass spectrometry applications. By utilizing these precise reference materials, analytical chemists can ensure accurate method validation and consistency in pharmacokinetic studies, supporting the reliable evaluation of this therapeutic agent throughout its development and clinical research phases.